Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01305408 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

399

Enrollment

INDUSTRY

Sponsor class

Conditions

Depression

Interventions

DRUG: Armodafinil
DRUG: Placebo

Sponsor

Cephalon